An Act relative to pharmaceutical access, costs and transparency
SECTION 1. Section 1 of chapter 6D of the General Laws, as appearing in the 2022 Official Edition, is hereby amended by inserting after the definition of “Alternative payment methodologies or methods” the following 2 definitions:- “Biosimilar”, a drug that is produced or distributed under a biologics license application approved under 42 U.S.C. 262(k)(3). “Brand name drug”, a drug that is: (i) produced or distributed pursuant to an original new drug application approved under 21 U.S.C. 355(c) except for: (a) any drug approved through an application submitted under section 505(b)(2) of the federal Food, Drug, and Cosmetic Act that is pharmaceutically equivalent, as that term is defined b…
An asterisk marks a vote the sheet records as entered after the roll closed. A member shown as "not linked" is a name on the sheet that did not resolve to exactly one member of the session's roster; it is left as printed rather than guessed.